

Precision Medicine

Question

What is the outlook for precision medicine, and does it present liability concerns or other challenges for healthcare providers?

Answer

The rapidly evolving approach known as precision medicine involves matching medical treatment with an individual's DNA, environment, and lifestyle. Using precision medicine, doctors and researchers will be able to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.

Although the day-to-day role of precision medicine in healthcare is still relatively limited, it is used for certain diagnostic and treatment approaches. For example, genetics and genomics are two components of precision medicine that have current applications in medical care and that will undoubtedly continue to advance over time.

The terms "genetics" and "genomics" are sometimes used interchangeably, but they are different. Genetics is the study of genes and how certain traits and diseases/conditions (such as sickle cell disease, hemophilia, and cystic fibrosis) are passed from generation to generation. Genomics is the study of all of an individual's genes (the genome) and how they interact with each other and the person's environment. Genomics can provide valuable information about diseases/conditions that aren't solely hereditary but often occur as a result of genetics, the environment, and other factors (such as cancer, heart disease, and asthma).¹

Because precision medicine is an evolving practice, issues related to liability are still largely unknown and will continue to emerge as the practice of precision medicine becomes more mainstream.

However, some risks and liability exposures have been identified with genetic testing, the diagnostic

approach that identifies mutations in chromosomes, genes, or proteins that may cause illness or disease. Areas of practice in which these have occurred include obstetrics, oncology, and cardiology.

A limited amount of MedPro Group's claims data indicates that allegations against healthcare providers resulted from:

- Failure to recommend, failure to order, or delays in ordering genetic testing
- Failure to refer a patient to a specialist for genetic counseling
- Failure to follow up on a patient's genetic testing results
- Failure to follow the genetic specialist's recommendations
- Misinterpretation of diagnostic studies
- Failure to understand risks like a medical geneticist would

Although genetic testing provides valuable information for diagnosing, treating, and preventing illness and disease, it has limitations. For example, a positive result from genetic testing for a healthy person doesn't always indicate disease development. Similarly, a negative result doesn't always guarantee that a certain disorder won't develop.²

Explaining these limitations to patients/families and setting clear expectations for genetic testing can help support informed decision-making and avoid misperceptions. Providers should ensure that information about genetic testing is presented to patients/families in ways that they can understand. Using a technique such as [teach-back](#) can help providers gauge patient comprehension and address inaccuracies or confusion.

Beyond liability concerns, precision medicine also presents ongoing ethical issues. The *AMA Journal of Ethics* identifies these potential ethical dilemmas as privacy, informed consent, shared decision-making, disclosure, social justice, valuation practices, regulation of human subjects research, etc.³

As precision medicine evolves and legal and ethical considerations become more apparent, so will best practices and strategies to address them. Healthcare providers who plan to incorporate aspects of precision medicine into practice should stay abreast of these developments and determine how best to partner with patients to maximize the value of precision care and mitigate potential risks.

Resources

- [American Cancer Society: Precision or Personalized Medicine](#)
- [American Medical Association: Education & Resources in Genetics & Personalized Medicine](#)
- [AMA Journal of Ethics: Ethics in Precision Medicine](#)
- [Brookings: Advancing Precision Medicine Through Agile Governance](#)
- [JAMA Insights: Genomics and Precision Health](#)
- [The Journal of Precision Medicine: Integrating Personalized Medicine into Preventive Care through Risk Stratification](#)
- [National Institutes of Health: National Human Genome Research Institute](#)
- [U.S. National Library of Health, National Institutes of Health: Genetics Home Reference](#)

Endnotes

¹ National Human Genome Research Institute. (2018, September 7). *Genetics vs. genomics fact sheet*. Retrieved from www.genome.gov/about-genomics/fact-sheets/Genetics-vs-Genomics

² Mayo Clinic. (2014, May 14). *Genetic testing*. Retrieved from www.mayoclinic.org/tests-procedures/genetic-testing/about/pac-20384827

³ Batten, J. N. (2018, September). How stratification unites ethical issues in precision health. *AMA Journal of Ethics*, 20(9), E798-803. doi: 10.1001/amajethics.2018.798

This document does not constitute legal or medical advice and should not be construed as rules or establishing a standard of care. Because the facts applicable to your situation may vary, or the laws applicable in your jurisdiction may differ, please contact your attorney or other professional advisors if you have any questions related to your legal or medical obligations or rights, state or federal laws, contract interpretation, or other legal questions.

MedPro Group is the marketing name used to refer to the insurance operations of The Medical Protective Company, Princeton Insurance Company, PLICO, Inc. and MedPro RRG Risk Retention Group. All insurance products are underwritten and administered by these and other Berkshire Hathaway affiliates, including National Fire & Marine Insurance Company. Product availability is based upon business and/or regulatory approval and may differ among companies.

© 2023 MedPro Group Inc. All rights reserved.